Jul 28, 2017 | News
SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1 infection. This drug has a new mechanism of action and is the...
Jul 14, 2017 | News
SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in...
![Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20%](https://healix.net/wp-content/uploads/pic-cuvitru.jpg)
Mar 20, 2017 | News
SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix receive a collection of clinical and...
Jun 13, 2016 | News
SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was conducted of 105 patients treated...
Jan 25, 2016 | News
SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric patients receiving...
Oct 10, 2015 | News
SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare Research and Quality, Healthcare Cost, and Utilization...
Page 10 of 13« First«...89101112...»Last »
Recent Comments